Press

Global CNS Therapeutics Strategic Report 2023: Market to Reach $199 Billion by 2030 – Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth

Nov 30 • 8 min read

The “CNS Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global CNS Therapeutics Market to Reach $199 Billion by 2030 The global market for CNS Therapeutics estimated at US$114.9 Billion in the year 2022, is projected to reach a revised size of US$199 Billion by 2030, growing at a CAGR of 7.1% over the…

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Nov 30 • 9 min read

Q4 Fiscal 2023 Highlights Fiscal 2023 Highlights All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 (“Q4…

Incannex Healthcare Announces Completion of its Redomiciliation to the United States

Nov 30 • 2 min read

Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex Healthcare from Australia to the United States has been implemented as of yesterday, November 28, 2023 New York time (November 29, 2023 Melbourne time). The shares of common stock of Incannex Healthcare Inc. issued yesterday in connection with…

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

Nov 29 • 3 min read

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its…

Wesana Health Announces Restructuring of Promissory Note Receivable

Nov 29 • 2 min read

Wesana Health Holdings Inc. (CSE: WESA.X) (OTCQB: WSNAF) (the “Company“), announced the execution of a Confidential Settlement and Release Agreement (“Settlement Agreement”) between Wesana Health Clinics Corp. (“Wesana”), a subsidiary of the Company, and APS Innovations LLC. (the “APS”) whereas the Parties agree to amend and restate the outstanding promissory note previously issued by APS to Wesana…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435